Ori Biotech

London, United Kingdom

Profile last updated: 2026-09-28

Platform Provider

CAR-T Cell Therapy

No confirmed program data — ClinicalTrials.gov verification pending · Last scored 2026-09-07

78.1

Signal Score

○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (1) ○ EMA GMP ○ MHRA GMP

Quick Facts: Ori Biotech

Signal Score: 78.1/100 (as of 2026-09-07)
Quality Compliance: 100.0/100
Headquarters: London, United Kingdom
Modalities: CAR-T, Cell Therapy
Active Programs: Data pending
Data Sources: FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By: CDMO Signal — independent CDMO intelligence platform

About Ori Biotech

CDMO.

Signal Score & Pillar Breakdown

Scores are being republished. Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.

Quality Compliance

FDA InspectionsNo US records on file

Operations —

No ClinicalTrials.gov facility matches confirmed for this manufacturer.

Programs — no verified data

Sponsors— no verified data

ModalitiesCAR-T, Cell Therapy

Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.

Financial Stability

Profile-based financial assessment

SEC FilingsPrivate company

Capacity

Profile-based capacity assessment

Recent Press1 articles

Attribution not established (1)

These records are excluded from this company’s established evidence because their attribution is unresolved. This describes an evidence-linking limitation, not an assessment of the underlying regulatory findings.